You are here

Home » Content

Posttransplant Eritrositoz ve Risk Faktörleri

Posttransplant Erythrocytosis and Risk Factors

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2011
DOI: 
10.5262/tndt.2011.1003.09

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIVE: The aim of this study was to determine the prevalence and risk factors of posttransplant erythrocytosis (PTE). MATERIAL and METHODS: The study included 96 patients who received a renal allograft between 2005-2009 years. PTE was defi ned as an elevated hematocrit level greater than 51% after renal transplantation in patients receiving an allograft. RESULTS: Of the 96 adult kidney recipients, 15 (15,6%) developed PTE. The mean time from transplantation to diagnosis was 7,3 ± 2,8 months ( range, 4,5-13 months ). Mean serum creatinine was 1,12 ±0,3 mg/dl (0,8-1,99 mg/dl) at the diagnosis of PTE. PTE was more frequent in male patients (p<0.05) and the patients with a long duration on dialysis prior to transplantation (p<0.05). There was no signifi cant difference in patient age, donor source, donor age and immunosuppressive therapy on comparing the PTE group and non PTE groups. None of the patients with erythrocytosis experienced thromboembolic events during follow-up. CONCLUSION: PTE developed in the fi rst year after transplantation. Male gender and a long duration on dialysis prior to transplantation are risk factors of PTE.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Çalışmamızın amacı böbrek nakli olmuş hastalarımızda posttransplant eritrositoz (PTE) sıklığını ve PTE için risk faktörlerini saptamaktır. GEREÇ ve YÖNTEMLER: 2005-2009 yılları arasında böbrek nakli olmuş 96 hastamız çalışmaya alındı. Böbrek naklinden sonraki izlemlerinde hematokrit düzeyi %51’in üzerinde olan hastalarımız da PTE geliştiği kabul edildi. BULGULAR: Böbrek nakli olmuş 96 hastanın 15’inde (%15,6) PTE gelişti. PTE tanı zamanı nakilden ortalama 7,3 ± 2,8 ay ( 4,5-13 ay arası ) sonra idi. Hastaların tanı anında kreatinin ortalaması 1,12 ±0,3 mg/dl (0,8-1,99 mg/dl) idi. PTE erkeklerde (p<0.05) ve nakilden önce uzun süre diyaliz tedavisi gören hastalarımızda daha sık gelişmişti (p<0.05). Hasta yaşı, verici kaynağı, verici yaşı, kullanılan bağışıklığı baskılayıcı tedavi bakımından PTE gelişen ve gelişmeyen hastalar arasında anlamlı bir fark yoktu. PTE’u olan hastalarımızın izlemlerinde tromboembolik bir olay gelişmedi SONUÇ: PTE sıklıkla nakilden sonraki ilk bir yıl içinde gelişmektedir. Erkek cinsiyet ve nakilden önce uzun süre diyaliz tedavisi artmış risk faktörleridir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_20_pp_260-264.pdf
  • 3
260-264
  • Turkish

REFERENCES

References: 

1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant
Work Group. KDIGO clinical practice guideline for the care of
kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3):
1-155
2. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE:
Posttransplant erythrocytosis. Kidney Int 2003; 63: 1187-1194
3. Dagher FJ, Ramos E, Erslev A, Karmi S, Alongi SV: Erythrocytosis
after renal allotransplantation: Treatment by removal of the native
kidneys. South Med J 1980; 73:940-942
4. Julian BA, Brantley RR Jr, Barker CV, Stopka T, Gaston RS, Curtis
JJ, Lee JY, Prchal JT: Losartan, an angiotensin II type 1 receptor
antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am
Soc Nephrol 1998; 9: 1104-1108
5. Basri N, Gendo MZ, Haider R, Abdullah KA, Hassan A, Shaheen
FA: Posttransplant erythrocytosis in renal transplant recipients
at Jeddah Kidney Center, Kingdom of Saudi Arabia. Exp Clin
Transplant 2007; 5: 607-609
6. Kessler M, Hestin D, Mayeux D, Mertes PM, Renoult E: Factors
predisposing to post-renal transplant erythrocytosis. A prospective
matched-pair control study. Clin Nephrol 1996; 45: 83-89
7. Einollahi B, Lessan-Pezeshki M, Nafar M, Pour-Reza-Gholi F,
Firouzan A, Farhangi F, Pourfarziani V: Erythrocytosis after renal
transplantation: Review of 101 cases. Transplant Proc 2005; 37:
3101-3102
8. Sumrani NB, Daskalakis P, Miles AM, Sarkar S, Markell MS,
Hong JH, Friedman EA, Sommer BG: Erythrocytosis after renal
transplantation. A prospective analysis. ASAIO J 1993; 39: 51-55
9. Razeghi E, Kaboli A, Pezeshki ML, Meysamie AP, Khatami
MR, Khashayar P: Risk factors of erythrocytosis post renal
transplantation. Saudi J Kidney Dis Transpl 2008; 19: 559-563
10. Charfeddine K, Zaghdane S, Yaich S, Hakim A, Hachicha J: Factors
predisposing to post-renal transplant erythrocytosis: A retrospective
study. Saudi J Kidney Dis Transpl 2008; 19: 371-377
11. Ghahramani NL, Malek-Hosseini SA, Rais-Jalali GA, Behzadi
S, Nezakatgoo N, Salahi H, Javid R, Bakhtiari Rad S: Factors
relating to posttransplant erythrocytosis in renal allograft recipients.
Transplant Proc 1998; 30: 828-829
12. Frei D, Guttmann RD, Gorman P: A matched-pair control study of
postrenal transplant polycythemia. Am J Kidney Dis 1982; 2: 36-42
13. Koziak K, Rell K, Lao M, Baczkowska T, Gaciong Z: Does
erythropoietin production after renal transplantation depend on the
type of immunosuppression? Nephron 1995; 71: 236-237
14. Qunibi WY, Barri Y, Devol E, al-Furayh O, Sheth K, Taher S:
Factors predictive of post-transplant erythrocytosis. Kidney Int
1991; 40: 1153-1159
15. Innes A, Pal CR, Dennis MJ, Ryan JJ, Morgan AG, Burden RP: Posttransplant
erythrocytosis and immunosuppression with cyclosporin:
A case-control study. Nephrol Dial Transplant 1991; 6: 588-591
16. Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM:
Postrenal transplant erythrocytosis: A review of 53 patients. Kidney
Int 1983; 23: 731-737

Thank you for copying data from http://www.arastirmax.com